Contineum Therapeutics Inc. (Class A) (CTNM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Contineum Therapeutics Inc. (Class A) (NASDAQ: CTNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.56 (+1.81% 1D, market cap $353.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTNM ranks #858 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTNM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.0%. By comparison, EBS (Emergent BioSolutions Inc.) holds a D grade (48/100 RQD, P/E 7.0x, ROIC 8.9%, cap $349.2M) and CAPR (Capricor Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
Per CTNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855175), Contineum Therapeutics Inc. (Class A) generated $190.6M in revenue (+33.7% YoY), -$60.0M in net income, and -$55.5M in free cash flow against $276.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CTNM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.40) and Max Pain ($10.04) forces dealer call-delta covering toward $18.67.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Contineum Therapeutics Inc. (Class A) (CTNM) advanced +1.81% to $9.56, trading at 26% of its 52-week range ($6.72 – $17.78). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
SAN DIEGO, October 29, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibr
Jones Trading analyst Debanjana Chatterjee maintains Contineum Therapeutics (NASDAQ:CTNM) with a Buy and raises the price target from $24 to $30.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +33.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CTNM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CTNM. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Contineum Therapeutics Inc. (Class A) (CTNM) ranks #858 by composite RQD confidence (28/100, grade E) and #494 by equity capitalization ($353.3M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CTNM at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTNM
ACTIVE
Contineum Therapeutics Inc. (Class A) | E | 28/100 | — | — | -29.0% | +1.81% | $353.3M | Benchmark Subject |
| EBS Emergent BioSolutions Inc. | D | 48/100 | 7.0x | 56.1% | 8.9% | -5.43% | $349.2M | /ebs-vs-ctnm → |
| CAPR Capricor Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +13.48% | $370.9M | /capr-vs-ctnm → |
| SPRY ARS Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -9.76% | $336.1M | /spry-vs-ctnm → |
| GALT Galectin Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | +0.30% | $335.6M | /galt-vs-ctnm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Contineum Therapeutics Inc. (Class A) (CTNM) reported GAAP revenue of $190.6M (+33.7% vs. FY2024 revenue of $142.5M , and +281.1% cumulative change since FY2023) , GAAP net income of -$60.0M, operating cash flow of -$55.3M, and free cash flow of -$55.5M (-66.5% YoY). On the balance sheet, CTNM closed FY2025 with $276.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $190.6M | -$60.0M | -$55.3M | -$55.5M | $276.6M | — |
| FY2024 (FY) | 2024-12-31 | $142.5M | -$42.3M | -$32.8M | -$33.4M | $212.8M | — |
| FY2023 (FY) | 2023-12-31 | $50.0M | $22.7M | $19.3M | $19.3M | — | — |
As of 2026-11-03, Contineum Therapeutics Inc. (Class A) (NASDAQ: CTNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.56 (+1.81% 1D, market cap $353.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTNM ranks #858 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTNM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.0%. By comparison, EBS (Emergent BioSolutions Inc.) holds a D grade (48/100 RQD, P/E 7.0x, ROIC 8.9%, cap $349.2M) and CAPR (Capricor Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
Per CTNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855175), Contineum Therapeutics Inc. (Class A) generated $190.6M in revenue (+33.7% YoY), -$60.0M in net income, and -$55.5M in free cash flow against $276.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CTNM last traded at $9.56 (+1.81% on volume of 369,020 shares), positioning the stock -22.90% below its 50-day simple moving average ($12.40) and -29.34% below its 200-day simple moving average ($13.53). Across its 52-week range of $6.72 to $17.78, CTNM sits at the 25.7% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.36 to $10.76).
Contineum Therapeutics Inc. (Class A) (CTNM) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $9.56 (+1.81% 1D, market capitalization $353.3M).
Contineum Therapeutics Inc. (Class A) (CTNM) is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — for FY 2025 and FY 2024, versus $50.0M for FY 2023, .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Contineum Therapeutics Inc. (Class A) (CTNM) reported $190.6M in annual revenue (up from $142.5M in FY2024, +33.7% YoY) and -$60.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($50.0M revenue, $22.7M net income) through FY2025, CTNM scaled operating cash flow to -$55.3M and free cash flow to -$55.5M, backed by $276.6M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CTNM carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Contineum Therapeutics Inc. (Class A) (CTNM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Contineum Therapeutics Inc. (Class A) (CTNM) market action, institutional positioning, and fundamental catalysts.
Don't sleep on CTNM's setup in Health Care. A cited Bristol Myers Squibb positive Phase 3 result drove a 27% share surge, and a rating upgrade to Buy was reported.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (28/100) backs up the fundamental quality.
Both sides have a point here — CTNM's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Sitting on the sidelines or leaning short CTNM above $9.39. Operating losses widened from -$50.9M in FY 2024 to -$68.1M in FY 2025 while free cash flow stayed negative at -$55.5M.. Until Fundamental Cash Engine (6/20) and FCF yield (-15.82%) inflect higher, upside is capped near $17.78.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).